Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
FLEX
Flex
$42.30
Chart
$30.53 (+38.55%)
$34.73 (+21.80%)
$43.85 (-3.53%)
$31.26 (+35.32%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
FLEX
Flex
Current Price
$42.30
Login to view Flex (FLEX) recommendation from the last 90 days from financial news and social media.
Chart
$30.53 (+38.55%)
$34.73 (+21.80%)
$43.85 (-3.53%)
$31.26 (+35.32%)
FLEX Latest Headlines
FlexShopper Partners with ICON Vehicle Dynamics to Expand Lease-to-Own Financing Options for Premium Off-Road Vehicle Upgrades. FlexShopper received Nasdaq notice regarding delayed SEC filings
Thu May 29, 2025
FlexShopper Partners with ICON Vehicle Dynamics to Expand Lease-to-Own Financing Options for Premium Off-Road Vehicle Upgrades. FlexShopper received Nasdaq notice regarding delayed SEC filings
Thu May 29, 2025
NRXBF In Great Position for Exciting Year. By NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point the company late last year announced some preclinical test results that have the potential to benefit thousands of patients and increase the value of NRXBF to investors. More recently however the company anno
Tue May 27, 2025
NRXBF In Great Position for Exciting Year. By NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point the company late last year announced some preclinical test results that have the potential to benefit thousands of patients and increase the value of NRXBF to investors. More recently however the company anno
Tue May 27, 2025
NRXBF In Great Position for Exciting Year. By NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point the company late last year announced some preclinical test results that have the potential to benefit thousands of patients and increase the value of NRXBF to investors. More recently however the company anno
Tue May 27, 2025
NRXBF In Great Position for Exciting Year. By NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point the company late last year announced some preclinical test results that have the potential to benefit thousands of patients and increase the value of NRXBF to investors. More recently however the company anno
Tue May 27, 2025
NRXBF In Great Position for Exciting Year. By NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point the company late last year announced some preclinical test results that have the potential to benefit thousands of patients and increase the value of NRXBF to investors. More recently however the company anno
Tue May 27, 2025
Imaflex Reports Q1 2025 Results. Provides Business Update. Accelerating Revenue Momentum and Robust 28% Growth in Adjusted EBITDAHighlightsRevenues of Adjusted net income1 of Adjusted EBITDA1 of Solid liquidity with MONTRÉAL) reports consolidated financial results for the first quarter (Q1) ended ".We are incredibly proud of how our team navigated a challenging quarter marked by a one-time cybersecurity incident". said Mr. Yazedjian President and Chief Executive Officer of Imaflex. &#
Tue May 27, 2025
Imaflex Reports Q1 2025 Results. Provides Business Update. Accelerating Revenue Momentum and Robust 28% Growth in Adjusted EBITDAHighlightsRevenues of Adjusted net income1 of Adjusted EBITDA1 of Solid liquidity with MONTRÉAL) reports consolidated financial results for the first quarter (Q1) ended ".We are incredibly proud of how our team navigated a challenging quarter marked by a one-time cybersecurity incident". said Mr. Yazedjian President and Chief Executive Officer of Imaflex. &#
Tue May 27, 2025
Imaflex Reports Q1 2025 Results. Provides Business Update. Accelerating Revenue Momentum and Robust 28% Growth in Adjusted EBITDAHighlightsRevenues of Adjusted net income1 of Adjusted EBITDA1 of Solid liquidity with MONTRÉAL) reports consolidated financial results for the first quarter (Q1) ended ".We are incredibly proud of how our team navigated a challenging quarter marked by a one-time cybersecurity incident". said Mr. Yazedjian President and Chief Executive Officer of Imaflex. &#
Tue May 27, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
FLEX Stock trends
FLEX Stock performance
FLEX Stock analysis
FLEX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
